Previous close | 2.4700 |
Open | 2.4100 |
Bid | 2.2300 x 800 |
Ask | 2.2500 x 800 |
Day's range | 2.2000 - 2.4800 |
52-week range | 1.4900 - 43.5000 |
Volume | |
Avg. volume | 667,770 |
Market cap | 11.016M |
Beta (5Y monthly) | 1.27 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6190 |
Earnings date | 10 Aug 2022 - 15 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.50 |
CHICAGO, July 20, 2022--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC informing it that Nasdaq has confirmed that the Company has regained compliance with the $1.00 per share minimum
CHICAGO, June 29, 2022--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that, following the implementation of a one-for-thirty reverse stock split at 5:00 p.m. EDT today, the Company’s common stock will begin trading on a split-adjusted basis on Nasdaq effective with the open of business tomor
CHICAGO, May 27, 2022--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that the Company’s Annual Meeting of Stockholders (the "Annual Meeting") held in virtual format on Friday, May 27, 2022 at 1:00 p.m. Central Time, was convened and adjourned until June 10, 2022 at 1:00 p.m. Central Time wit